Immune profiling leads to implications for immunotherapy for NF1-associated tumors

June 12, 2017, Nationwide Children's Hospital

Neurofibromatosis type 1 (NF1)—an autosomal dominant disorder affecting approximately one in every 3,500 people—results in dysfunctional neurofibromin, a protein expressed throughout the body and involved in the RAS signaling pathway. Virtually all patients with NF1 develop benign peripheral nerve sheath neurofibromas, which are believed to arise from aberrant Schwann cells. Additionally, some tumors undergo malignant transformation.

NF1-associated tumors are notoriously difficult to treat. While the underlying primary genetic defect and impact on RAS signaling is well described, recent studies suggest contribution of immune dysfunction to pathogenesis and .

Recently a team in the Center for Childhood Cancer and Blood Diseases in The Research Institute at Nationwide Children's Hospital led a study published in Oncotarget that further seeks to define the immunogenic profiles of these NF1-associated tumors in the hopes of identifying targeted immunotherapy options. The collaborative study included researchers from the Center for Childhood Cancer and Blood Diseases, the Division of Hematology, Oncology and Blood and Marrow Transplant and the Division of Anatomic Pathology at Nationwide Children's, in addition to investigators at Cincinnati Children's Hospital Medical Center.

Dr. Haworth and her colleagues evaluated the expression of human leukocyte antigen (HLA)-A/-B/-C, beta-2-microglobulin and T cell inhibitory ligands PD-L1 and CTLA-4 by microarray gene analysis and flow cytometry.

Additionally they examined HLA, B2M, and PD-L1 expression on tumor samples by immunohistochemistry.

Finally, they evaluated several tumors from a single patient over time to observe trends in immunogenicity over time.

"Some NF1-associated tumors, both benign (nodular neurofibromas, and plexiform neurofibromas) and malignant (malignant peripheral nerve sheath tumors), display immunologic profiles that suggest their potential to respond to T cell-based immunotherapeutic modalities," says Kellie Haworth, MD, fellow in the Cripe Lab in the Center for Childhood Cancer and Blood Diseases. "While these tumors show potential targets for T cell-based immunotherapies, the maximal therapeutic efficacy of this approach is complicated by tumor heterogeneity within tumor subtypes - and sometimes even within the same tumor sample."

"While there is no evidence at this present time to suggest that specific immune-based therapeutic modalities will be more efficacious than the currently accepted standard of care treatment strategies for these tumors, our findings do support further investigations which utilize immunotherapies for some NF1-associated tumors such as MPNST and plexiform neurofibromas," says Dr. Haworth. "We would encourage the incorporation of immunologic profiling into prospective clinical immunotherapeutic studies."

According to Dr. Haworth, the next step will be testing whether the immunologic profiles observed in these tumors will translate into something clinically useful - either as a predictive biomarker for response to immunotherapies or as a prognostic correlate.

"If we can prove that tumoral immunologic profiling, which is relatively cheap and easy to perform, indicates which type of immune-based therapy will work to ultimately eradicate the tumor, we can potentially optimize our therapeutic approach for each patient and maximize our chances for efficacy," she explains.

"The intricacies of each individual patient's immune system and the heterogeneity of his or her tumor(s) will likely play a large role in overall response. Ultimately, this may prove to be a highly individualized, patient immunology-based, tumor profile-based strategy. And if it works, it may change both the management and outcomes of patients with these difficult tumors."

Explore further: Biomarker MIA shows presence of neurofibromas

More information: Kellie B. Haworth et al, Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: Implications for immunotherapy, Oncotarget (2017). DOI: 10.18632/oncotarget.18301

Related Stories

Biomarker MIA shows presence of neurofibromas

July 4, 2011
Neurofibromatosis (NF1) is a genetic condition which affects one in every 3,000 people. The severity of symptoms can range from benign 'cafe au lait' patches on the skin, through small tumors under the skin and deep plexiform ...

Study identifying cell of origin for large, disfiguring nerve tumors lays groundwork for development

November 11, 2014
UT Southwestern Medical Center researchers have determined the specific type of cell that gives rise to large, disfiguring tumors called plexiform neurofibromas, a finding that could lead to new therapies for preventing growth ...

First study of Oncolytic HSV-1 in children and young adults with cancer indicates safety, tolerability

May 11, 2017
HSV1716 - an oncolytic herpes simplex virus-1 - has been studied in adults via injection into the brain and superficial tumors. Now, a team of researchers at Nationwide Children's Hospital and Cincinnati Children's Hospital ...

Silencing cancer cell communication may reduce the growth of tumors

January 30, 2017
In several types of cancer, elevated expression of the chemokine receptor CCR4 in tumors is associated with poor patient outcomes. Communication through CCR4 may be one mechanism that cancer cells use to create a pro-tumor ...

Matching tumor size to strength of immune response allows melanoma drug tailoring

April 10, 2017
Despite the success of immunotherapies based on blocking the programmed cell death 1 (PD-1) receptor protein in metastatic melanoma patients, more than half do not experience a lasting benefit by seeing their tumors shrink. ...

Special T cells that target solid tumors offer potential treatment for pediatric and adult cancers

September 14, 2016
Adoptive cell-therapies, in which a patient's own immune cells are used to recognize and target tumors, have shown breakthrough results for patients with certain B-cell malignancies, or cancers of the blood, but this therapy ...

Recommended for you

Lung cancer drug could be repurposed to target 'zombie' proteins linked to leukemia

September 25, 2018
A new study by scientists at the University of Liverpool highlights how a clinically-approved lung cancer drug could potentially be 'repurposed' to design new treatments for future cancer therapies.

A protein called vaccinia-related kinase 1 may help cancer establish itself in new areas of the body during metastasis

September 25, 2018
Sometimes negative results can point researchers in the right direction.

Combo therapy of prostatectomy plus radiotherapy may improve survival in prostate cancer

September 25, 2018
High-risk prostate cancer, that which has continued to grow but not yet metastasized, is commonly treated with combination therapies. Each method has pros and cons, but there is little clarity whether one might be more effective ...

Brigatinib becomes potential new first-line option for ALK-positive non-small lung cancer

September 25, 2018
Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for ...

Two studies describe improved approach to bone marrow transplant

September 25, 2018
Two recent studies in the journal Leukemia present a new approach for bone marrow donation and transplant that preclinical laboratory tests suggest could make the life-saving procedure safer and more effective for patients.

Unhealthy lifestyle responsible for 45,000 predicted cases of bowel cancer in next decade

September 25, 2018
A UNSW study shows that a large proportion of bowel cancers in Australia are preventable by adopting a healthy lifestyle – particularly for men.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.